Afya's core medical education franchise continues to compound revenue at 8.1% YoY in 2026Q2, underpinned by gross margins that have held between 61.6% and 68.9% over the past ten quarters, reflecting durable pricing power despite a maturing base. The balance s...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | $0.45+15.7% vs $0.39 | $187M-1.2% vs $190M |
Q2 2026 May 7, 2026 | $0.56+5.7% vs $0.53 | $193M-5.8% vs $204M |
Q2 2026 Mar 12, 2026 | $0.41+7.9% vs $0.38 | $166M-0.8% vs $168M |
Q4 2025 Nov 12, 2025 | $0.38+18.8% vs $0.32 | $174M-0.3% vs $175M |
Afya Limited (NASDAQ: AFYA - Get Free Report) was the target of a large increase in short interest during the month of September. As of September 15th, there was short interest totaling 1,411,623 shares, an increase of 163.2% from the August 31st total of 536,316 shares. Based on an average daily volume of 274,094 shares, the
Shares of Afya Limited (NASDAQ: AFYA - Get Free Report) reached a new 52-week low during trading on Saturday. The company traded as low as $12.75 and last traded at $13.00, with a volume of 591542 shares traded. The stock had previously closed at $13.73. Key Afya News Here are the key news stories impacting Afya
Afya Limited (NASDAQ: AFYA - Get Free Report) has been assigned an average recommendation of "Hold" from the seven ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and one has issued a buy recommendation on the
Afya Limited (AFYA) M&A Call Transcript
Benchmark AFYA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Afya Limited (AFYA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $12.22 | $1.1B | 7.85 | 9.69% | 20.35% | 16.04% | — | |
| $31.91 | $2B | 13.19 | 24.2% | 20.63% | 17.7% | — | |
| $38.62 | $5.41B | 20.43 | 8.64% | 17.57% | 28.6% | — | |
| $79.72 | $1.81B | 14.71 | 3.96% | 10.46% | 8.19% | — | |
| $1149.61 | $4.98B | 17.30 | 2.52% | 10.69% | 11.39% | — | |
| $155.79 | $4.13B | 20.21 | 7.07% | 19.63% | 31.24% | — |
Afya Limited (AFYA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when AFYA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Afya Limited (AFYA) stock FAQ — growth, dividends, profitability & financials explained
Afya Limited (AFYA) reported $3.84B in revenue for fiscal year 2025. This represents a 1679% increase from $216.0M in 2017.
Afya Limited (AFYA) grew revenue by 9.7% over the past year. This is steady growth.
Yes, Afya Limited (AFYA) is profitable, generating $784.6M in net income for fiscal year 2025 (20.4% net margin).
Afya Limited (AFYA) has a return on equity (ROE) of 16.0%. This is reasonable for most industries.
Afya Limited (AFYA) generated $1.16B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
